SELLAS Life Sciences Group, Inc.
SLS · Pharmaceutical Preparations · 186.0M shares · +66%/yr ↑ dilution · EDGAR filings ↗
Net buyback after stock comp: $2M (gross $3M, SBC $2M)
Reference price $1.59 · est. market cap ~$296M — last insider purchase, 2025-11-19 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — oncology clinical, well-funded.
Strengths
- Liquidity — current ratio 10.7 (80th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Chronic dilutionShare count +66%/yr over 4y (dilution, book value/share -55%)
- Notable holderHeld by 4 notable fund(s): STATE STREET CORP, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC +1 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Return on equity
-37.9%
Return on assets
-34.3%
Current ratio
10.7×
Tangible book value
$69M
Cash & investments
$72M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-16 | Stergiou Angelos M. | Grant | 1.1M | — |
| 2026-01-07 | Varian John | Grant | 50K | — |
| 2026-01-07 | VAN NOSTRAND ROBERT L | Grant | 50K | — |
| 2026-01-07 | SCHEINBERG DAVID A | Grant | 50K | — |
| 2026-01-07 | CICIC DRAGAN | Grant | 300K | — |
| 2026-01-07 | Burns John Thomas | Grant | 300K | — |
| 2026-01-07 | Kalin Katherine Bach | Grant | 50K | — |
| 2026-01-07 | Wasman Jane | Grant | 50K | — |
| 2025-12-03 | CICIC DRAGAN | Other | 64K | $1.50 |
| 2025-12-03 | Burns John Thomas | Other | 59K | $1.50 |
| 2025-12-03 | Stergiou Angelos M. | Other | 187K | $1.50 |
| 2025-11-19 | Kalin Katherine Bach | Buy | 63K | $1.59 |
| 2025-06-12 | VAN NOSTRAND ROBERT L | Buy | 10K | $1.48 |
| 2025-05-30 | Wasman Jane | Buy | 20K | $1.69 |
| 2025-05-22 | Kalin Katherine Bach | Buy | 20K | $1.80 |
| 2025-01-10 | Burns John Thomas | Grant | 113K | — |
| 2025-01-10 | Burns John Thomas | Grant | 81K | — |
| 2025-01-10 | Stergiou Angelos M. | Grant | 257K | — |
| 2025-01-10 | Stergiou Angelos M. | Grant | 244K | — |
| 2025-01-10 | SCHEINBERG DAVID A | Grant | 12K | — |
| 2025-01-10 | Wasman Jane | Grant | 12K | — |
| 2025-01-10 | VAN NOSTRAND ROBERT L | Grant | 12K | — |
| 2025-01-10 | Kalin Katherine Bach | Grant | 12K | — |
| 2025-01-10 | Varian John | Grant | 12K | — |
| 2025-01-10 | CICIC DRAGAN | Grant | 113K | — |
| 2025-01-10 | CICIC DRAGAN | Grant | 81K | — |
All non-derivative Form 4 activity (SEC), newest first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-25 | 2026-06-24 | 0001104659-26-077556 ↗ |
| 8-K | 2026-06-18 | 2026-06-16 | 0001104659-26-075775 ↗ |
| 8-K | 2026-06-02 | 2026-06-02 | 0001104659-26-069251 ↗ |
| 10-Q | 2026-05-12 | 2026-03-31 | 0001390478-26-000008 ↗ |
| 8-K | 2026-05-12 | 2026-05-12 | 0001390478-26-000009 ↗ |
| 8-K | 2026-03-19 | 2026-03-19 | 0001390478-26-000004 ↗ |
| 10-K | 2026-03-19 | 2025-12-31 | 0001390478-26-000003 ↗ |
| 8-K | 2026-03-11 | 2026-03-11 | 0001104659-26-026384 ↗ |
| 8-K | 2026-01-08 | 2026-01-07 | 0001104659-26-001957 ↗ |
| 10-Q | 2025-11-12 | 2025-09-30 | 0001390478-25-000020 ↗ |
| 8-K | 2025-11-12 | 2025-11-12 | 0001390478-25-000021 ↗ |
| 8-K | 2025-10-27 | 2025-10-24 | 0001104659-25-102345 ↗ |